vs
Side-by-side financial comparison of CSP INC (CSPI) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $12.0M, roughly 1.7× CSP INC). CSP INC runs the higher net margin — 0.8% vs -20.4%, a 21.2% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs -23.2%). Sight Sciences, Inc. produced more free cash flow last quarter ($-2.0M vs $-3.0M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -6.3%).
CSP Inc. is a U.S.-based technology firm offering cybersecurity solutions, managed IT services, high-performance computing systems, and IT consulting support. It serves enterprises across healthcare, finance, manufacturing, and public sectors in North America and select global markets.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CSPI vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $20.4M |
| Net Profit | $91.0K | $-4.2M |
| Gross Margin | 39.3% | 87.3% |
| Operating Margin | -0.9% | -18.0% |
| Net Margin | 0.8% | -20.4% |
| Revenue YoY | -23.2% | 6.9% |
| Net Profit YoY | -80.7% | 64.9% |
| EPS (diluted) | $0.01 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.0M | $20.4M | ||
| Q3 25 | $14.5M | $19.9M | ||
| Q2 25 | $15.4M | $19.6M | ||
| Q1 25 | $13.1M | $17.5M | ||
| Q4 24 | $15.7M | $19.1M | ||
| Q3 24 | $13.0M | $20.2M | ||
| Q2 24 | $13.1M | $21.4M | ||
| Q1 24 | $13.7M | $19.3M |
| Q4 25 | $91.0K | $-4.2M | ||
| Q3 25 | $-191.0K | $-8.2M | ||
| Q2 25 | $-264.0K | $-11.9M | ||
| Q1 25 | $-108.0K | $-14.2M | ||
| Q4 24 | $472.0K | $-11.8M | ||
| Q3 24 | $-1.7M | $-11.1M | ||
| Q2 24 | $-185.0K | $-12.3M | ||
| Q1 24 | $1.6M | $-16.3M |
| Q4 25 | 39.3% | 87.3% | ||
| Q3 25 | 36.6% | 86.4% | ||
| Q2 25 | 28.8% | 84.8% | ||
| Q1 25 | 32.0% | 86.2% | ||
| Q4 24 | 29.1% | 86.8% | ||
| Q3 24 | 28.4% | 83.9% | ||
| Q2 24 | 35.0% | 85.8% | ||
| Q1 24 | 47.3% | 85.5% |
| Q4 25 | -0.9% | -18.0% | ||
| Q3 25 | -3.7% | -39.7% | ||
| Q2 25 | -7.9% | -59.6% | ||
| Q1 25 | -7.6% | -79.2% | ||
| Q4 24 | -2.3% | -62.5% | ||
| Q3 24 | -15.7% | -55.7% | ||
| Q2 24 | -5.5% | -59.2% | ||
| Q1 24 | 9.0% | -76.4% |
| Q4 25 | 0.8% | -20.4% | ||
| Q3 25 | -1.3% | -41.0% | ||
| Q2 25 | -1.7% | -61.0% | ||
| Q1 25 | -0.8% | -80.8% | ||
| Q4 24 | 3.0% | -62.1% | ||
| Q3 24 | -12.7% | -54.9% | ||
| Q2 24 | -1.4% | -57.7% | ||
| Q1 24 | 11.6% | -84.4% |
| Q4 25 | $0.01 | $-0.07 | ||
| Q3 25 | $-0.02 | $-0.16 | ||
| Q2 25 | $-0.03 | $-0.23 | ||
| Q1 25 | $-0.01 | $-0.28 | ||
| Q4 24 | $0.05 | $-0.23 | ||
| Q3 24 | $-0.17 | $-0.22 | ||
| Q2 24 | $-0.02 | $-0.25 | ||
| Q1 24 | $0.16 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.9M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $44.8M | $63.9M |
| Total Assets | $69.2M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.9M | $92.0M | ||
| Q3 25 | $27.4M | $92.4M | ||
| Q2 25 | $26.3M | $101.5M | ||
| Q1 25 | $29.5M | $108.8M | ||
| Q4 24 | $30.7M | $120.4M | ||
| Q3 24 | $30.6M | $118.6M | ||
| Q2 24 | $28.9M | $118.2M | ||
| Q1 24 | $27.1M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $44.8M | $63.9M | ||
| Q3 25 | $44.6M | $64.3M | ||
| Q2 25 | $47.5M | $70.0M | ||
| Q1 25 | $47.5M | $77.6M | ||
| Q4 24 | $47.5M | $87.5M | ||
| Q3 24 | $47.3M | $95.0M | ||
| Q2 24 | $48.1M | $101.6M | ||
| Q1 24 | $48.2M | $109.2M |
| Q4 25 | $69.2M | $115.3M | ||
| Q3 25 | $71.2M | $116.3M | ||
| Q2 25 | $66.8M | $122.0M | ||
| Q1 25 | $67.1M | $129.7M | ||
| Q4 24 | $67.5M | $142.8M | ||
| Q3 24 | $69.4M | $143.6M | ||
| Q2 24 | $66.8M | $149.7M | ||
| Q1 24 | $64.2M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-1.8M |
| Free Cash FlowOCF − Capex | $-3.0M | $-2.0M |
| FCF MarginFCF / Revenue | -25.1% | -9.7% |
| Capex IntensityCapex / Revenue | 0.9% | 0.8% |
| Cash ConversionOCF / Net Profit | -32.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-2.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $-1.8M | ||
| Q3 25 | $1.9M | $-8.7M | ||
| Q2 25 | $-3.3M | $-7.5M | ||
| Q1 25 | $1.9M | $-11.6M | ||
| Q4 24 | $1.7M | $-3.5M | ||
| Q3 24 | $-1.5M | $362.0K | ||
| Q2 24 | $2.4M | $-9.5M | ||
| Q1 24 | $1.7M | $-9.8M |
| Q4 25 | $-3.0M | $-2.0M | ||
| Q3 25 | $1.7M | $-8.9M | ||
| Q2 25 | $-3.3M | $-7.8M | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $1.7M | $-3.6M | ||
| Q3 24 | $-1.5M | $311.0K | ||
| Q2 24 | $2.4M | $-9.5M | ||
| Q1 24 | $1.6M | $-9.9M |
| Q4 25 | -25.1% | -9.7% | ||
| Q3 25 | 11.5% | -44.7% | ||
| Q2 25 | -21.7% | -39.6% | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 10.8% | -18.9% | ||
| Q3 24 | -11.7% | 1.5% | ||
| Q2 24 | 17.9% | -44.7% | ||
| Q1 24 | 11.9% | -51.4% |
| Q4 25 | 0.9% | 0.8% | ||
| Q3 25 | 1.6% | 0.9% | ||
| Q2 25 | 0.4% | 1.1% | ||
| Q1 25 | 0.1% | 0.0% | ||
| Q4 24 | 0.3% | 0.7% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.3% | 0.4% | ||
| Q1 24 | 0.1% | 0.6% |
| Q4 25 | -32.04× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSPI
| Products | $6.7M | 56% |
| Services | $5.3M | 44% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
